Press release
Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight
The 7MM Graft Versus Host Disease (GvHD) market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative therapies such as ZEMAIRA, EQ001, MaaT013, and RGI-2001, among others. According to DelveInsight's comprehensive analysis, key pharmaceutical companies including ICSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, Medac, and others leading innovation in this space.
DelveInsight's "Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast - 2034 [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides an in-depth understanding of Graft Versus Host Disease (GvHD), historical and forecasted epidemiology, as well as the Graft Versus Host Disease market trends in the 7MM which include the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. The GvHD market forecast anticipates a CAGR of 8.2% through 2034 over the study period (2020-2034) from USD 1.3 Billion in 2023.
Regionally, the United States represents around 70% of the GvHD market, thanks to favorable reimbursement policies and rapid adoption of new, premium-priced therapies. The EU4 and the UK together account for about 19% of the GvHD market.
Download the GvHD market report to understand which factors are driving the Graft Versus Host Disease therapeutic market @ Graft Versus Host Disease Market Trends [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
The report also analyzes historical and projected epidemiology segmented by total allogenic transplant cases, total Graft Versus Host Disease prevalence, type-specific cases of Graft Versus Host Disease, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, Graft Versus Host Disease cases by grading, Graft Versus Host Disease cases by organ involvement, total treated cases of Graft Versus Host Disease, and mortality adjusted treated cases of Graft Versus Host Disease.
DelveInsight estimates approximately 52K cases of Graft Versus Host Disease in the 7MM. In 2023, the EU4 and the UK recorded the highest incidence of Grade D[IV] Graft-Versus-Host Disease, aligning with patterns observed in hematologic malignancy transplants.
Discover evolving trends in Graft Versus Host Disease patient pool forecasts @ Graft Versus Host Disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The Graft Versus Host Disease Treatment Market Report provides insights into current GvHD treatment practices, emerging drugs, market share of individual therapies, and forecasts for the 7MM GvHD market size from 2020 to 2034. Current Graft Versus Host Disease therapies include steroids, NIKTIMVO, JAKAFI, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others.
Graft Versus Host Disease Treatment is evolving from broad immunosuppression to targeted and cell-based therapies. JAKAFI (ruxolitinib), a JAK1/JAK2 inhibitor, is a cornerstone of GvHD treatment and generates substantial revenue due to its proven efficacy in steroid-refractory cases.
DelveInsight's analysis indicates that the GvHD clinical trials market is highly active, with numerous investigational therapies in various stages of development. Notable candidates include ZEMAIRA (CSL Behring), EQ001 (Equillium/Biocon), MaaT013 (MaaT Pharma), RGI-2001 (REGiMMUNE), MC0518 (Medac), RLS-0071 (ReAlta Life Sciences), VIMSELTINIB (Deciphera Pharmaceuticals), ARSCIMED (Medsenic/BioSenic), ASC-930 (ASC Therapeutics), CYP-001 (Cynata Therapeutics), F-652 (Yifan Pharmaceutical), and APRAGLUTIDE (Ironwood), among others.
Unlock which Graft Versus Host emerging Disease drug is expected to capture the largest market share in 7MM by 2034. Visit the Graft Versus Host Disease Market Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
In January 2025, the FDA approved Incyte's and Syndax's Niktimvo (axatilimab-csfr) in 9 mg and 22 mg vial sizes for the treatment of chronic graft-versus-host disease (GVHD) in adults and pediatric patients based on data from the AGAVE-201 trial. This demonstrates encouraging progress in the graft versus host disease clinical trials market.
Upcoming milestones may include potential label expansions of cellular therapies like mesenchymal stromal cells, which could redefine first-line treatment strategies. However, challenges remain, such as standardizing response criteria across clinical trials and addressing the financial strain associated with chronic graft versus host disease treatment. DelveInsight's report emphasizes that overcoming these challenges will require collaboration among pharmaceutical stakeholders and transplant networks to optimize patient stratification and track outcomes effectively.
Table of Contents
1.
Key Insights
2.
Report Introduction
3.
GvHD Market Overview at a Glance
4.
Executive Summary
5.
Key Events
6.
Disease Background and Overview
7.
Methodology
8.
Epidemiology and Patient Population
9.
Patient Journey
10.
Marketed Drugs
11.
Emerging Drugs
12.
GvHD - 7MM Market Analysis
13.
KOL Views
14.
Unmet Needs
15.
SWOT Analysis
16.
Market Access and Reimbursement
16.1.
The US
17.
Appendix
18.
DelveInsight Capabilities
19.
Disclaimer
20.
About DelveInsight
Related Reports
Graft versus host disease (GvHD) Pipeline Insight [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Graft versus host disease Pipeline Insight provides comprehensive insights about the GvHD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the GvHD companies, including Abbisko Therapeutics, Equillium, Theriva Biologics, Seres Therapeutics, CytoMed Therapeutics, Beijing Tide Pharmaceutical Co., Ltd, CTI BioPharma, ViGenCell Inc., Lipella Pharmaceuticals, Cellestia Biotech, Seres Therapeutics, Jiangsu HengRui Medicine Therapeutics, Genentech, AltruBio, Orca Bio, GSK and Amgen among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-is-projected-for-substantial-expansion-from-usd-13-billion-in-2023-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graft Versus Host Disease Market is Projected for Substantial Expansion from USD 1.3 Billion in 2023| DelveInsight here
News-ID: 3915489 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Graft
Bone Graft and Graft Substitute Market Latest Research, Top Impacting Factors, G …
The "Bone Graft and Graft Substitute Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. A bone graft is a surgical treatment used to repair problems with bones or joints. Bone grafting, or transplanting of bone tissue, is useful in fixing bones that are impaired from trauma or problem joints. Bone growth around an embedded…
Synthetic Bioactive Bone Graft Substitutes Market Growing need for bone graft su …
Global Synthetic Bioactive Bone Graft Substitutes Market Overview:
The Synthetic Bioactive Bone Graft Substitutes market is a broad category that includes a wide range of products and services related to various industries. This market comprises companies that operate in areas such as consumer goods, technology, healthcare, and finance, among others.
In recent years, the Synthetic Bioactive Bone Graft Substitutes market has experienced significant growth, driven by factors such as increasing consumer demand,…
Bone Graft Substitutes Market Size to Hit $3.8 Billion by 2028 | Bone Graft Subs …
Market Overview:
According to our experience research team, Bone Graft Substitutes Market was valued at USD 2.7 Billion in 2021, and the global Bone Graft Substitutes industry is projected to reach a value of USD 3.8 Billion by 2028, at a CAGR of 5.9% during the forecast period 2022-2028
Vantage Market Research is a collection of market research studies on several industries, such as Chemicals, semiconductors & Electronics, Food & Beverages Technology,…
Graft Delivery Devices Market Facts, Figures and Analytical Insights, 2017 to 20 …
Global Graft Delivery Devices Market: Snapshot
Graft delivery relates to the surgically transplantation of a piece of living tissues and the procedure can be highly essential as well as complex at the same time. Consequently, technological advancements have paved way to graft delivery devices that can minimally breach bone, fat, and vascular parts of the body to transfer drugs during plastic and reconstructive surgeries as well as arthroscopic and orthopedic surgeries.…
Glass Graft Polyols Market 2019| BASF SE, Sinopec, Shell, Oltchim, The Dow Chemi …
Market Research Hub (MRH) has actively included a new research study titled “Global Graft Polyols Market” Research Report 2019 to its wide online repository. The concerned market is discoursed based on a variety of market influential factors such as drivers, opportunities and restraints. This study tends to inform the readers about the current as well as future market scenarios extending up to the period until forecast period limit; 2025. In…
Global Vascular Graft Market Growth Analysis Report 2018-2025Global Vascular Gra …
Research Report 2018-2025 on "Global Vascular Graft Market" which provides an outlook of current market value of Vascular Graft Market as well as the expected forecast of Rate on Investment (ROI) with growing CAGR of XX% in Vascular Graft Market by the end of 2025. The report on the global Vascular Graft market uses the top-down and bottom-up approaches to define, analyze, and describe the Vascular Graft market 2018 trends…
